daraxonrasib

U.S. Biotech Sector Navigates Approaching Patent Cliff and Foreign Licensing Restrictions Amid Breakthrough Cancer Therapies

A political and regulatory battle over foreign licensing in Washington is threatening to reshape the U.S. pharmaceutical landscape, even as…

Read More »